Ubs Group Ag Pasithea Therapeutics Corp. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$0.44 - $0.63 $3,010 - $4,309	-6,841 Reduced 98.8%	83 $0
Q2 2023 Aug 11, 2023	BUY	$0.31 - $0.5 $2,146 - $3,462	6,924 New	6,924 $3,000
Q4 2022 Feb 08, 2023	BUY	$0.55 - $26.0 $4,004 - $189,280	7,280 Added 133.53%	12,732 $8,000
Q3 2022 Nov 10, 2022	SELL	$0.08 - $26.4 $588 - $194,119	-7,353 Reduced 57.42%	5,452 $7,000
Q2 2022 Aug 10, 2022	BUY	$16.52 - $27.0 $211,538 - $345,735	12,805 New	12,805 $13,000
Q4 2021 Feb 14, 2022	SELL	$28.8 - $112.0 $94,752 - $368,480	-3,290 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$54.8 - $71.2 $180,292 - $234,248	3,290 New	3,290 $10,000

Ticker KTTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,398,700
Market Cap $74.7M
Description
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.